Skip to main content
Top
Published in: Pituitary 1/2007

01-03-2007 | Case Report

Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function

Authors: Eigil Husted Nielsen, Jörgen Lindholm, Peter Laurberg, Per Bjerre, Jens Sandahl Christiansen, Claus Hagen, Svend Juul, Jesper Jørgensen, Anders Kruse, Kirstine Stochholm

Published in: Pituitary | Issue 1/2007

Login to get access

Abstract

The incidence of clinically significant, nonfunctioning pituitary adenoma, requiring surgical treatment, has not been established. According to previous studies, both surgery type and subsequent radiotherapy may have an impact on quality of life (QOL), and some studies have shown increased cardiovascular mortality in patients with pituitary disease. We studied all patients with functionless, suprasellar pituitary adenoma who were operated on during the period 1985–1996 (N = 192; transsphenoidal surgery = 160, craniotomy = 32). QOL was evaluated from Short Form 36 and Major Depression Inventory questionnaires. Causes of death were obtained from the Danish Register of Causes of Death. Incidence was 5.6/mill/year. Postoperatively, 27% of the patients had normal pituitary function and 27% were panhypopituitary. Fifty three patients had died. Death from cardiovascular, cerebrovascular and malignant diseases was not increased. Overall, QOL was not different from QOL of an age- and sex matched background population. QOL was, however, impaired in patients who had undergone craniotomy as compared to patients undergoing transsphenoidal surgery. QOL was not reduced in hypopituitary patients or in patients receiving radiotherapy.
Literature
1.
go back to reference Ezzat S, Asa SL., Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas. Cancer 101:613–619PubMedCrossRef Ezzat S, Asa SL., Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas. Cancer 101:613–619PubMedCrossRef
2.
go back to reference Page RCL, Hammersley MS, Burke CW, Wass JAH (1997) An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol 46:401–406CrossRef Page RCL, Hammersley MS, Burke CW, Wass JAH (1997) An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol 46:401–406CrossRef
3.
go back to reference Johnson MD, Woodburn CJ, Vance ML (2003) Quality of life in patients with a pituitary adenoma. Pituitary 6:81–87PubMedCrossRef Johnson MD, Woodburn CJ, Vance ML (2003) Quality of life in patients with a pituitary adenoma. Pituitary 6:81–87PubMedCrossRef
4.
go back to reference Peace KA, Orme SM, Sebastian JP, Thompson AR, Barnes S, Ellis A, Belchet PE (1997) The effect of treatment variables on mood and social adjustment in adult patients with pituitary disease. Clin Endocrinol 46:445–450CrossRef Peace KA, Orme SM, Sebastian JP, Thompson AR, Barnes S, Ellis A, Belchet PE (1997) The effect of treatment variables on mood and social adjustment in adult patients with pituitary disease. Clin Endocrinol 46:445–450CrossRef
5.
go back to reference Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JWA, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metabol 91:3364–3369CrossRef Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JWA, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metabol 91:3364–3369CrossRef
6.
go back to reference Rosen T, Bengtsson B-A (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288PubMedCrossRef Rosen T, Bengtsson B-A (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288PubMedCrossRef
7.
go back to reference Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metabol 81:1169–1172CrossRef Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metabol 81:1169–1172CrossRef
8.
go back to reference Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 46:75–81CrossRef Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 46:75–81CrossRef
9.
go back to reference Bates AS, Bullivant B, Sheppard MC, Stewart PM (1999) Life expectancy following surgery for pituitary tumours. Clin Endocrinol 50:315–319CrossRef Bates AS, Bullivant B, Sheppard MC, Stewart PM (1999) Life expectancy following surgery for pituitary tumours. Clin Endocrinol 50:315–319CrossRef
10.
go back to reference Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM and the West Midlands Prospective Hypopituitary Study Group (2001) Association between premature mortality and hypopituitarism. Lancet 357:425–431 Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM and the West Midlands Prospective Hypopituitary Study Group (2001) Association between premature mortality and hypopituitarism. Lancet 357:425–431
11.
go back to reference Svensson J, Bengtsson B-A, Rosen T, Oden A, Johansson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with and without growth hormone replacement therapy. J Clin Endocrinol Metabol 89:3306–3312CrossRef Svensson J, Bengtsson B-A, Rosen T, Oden A, Johansson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with and without growth hormone replacement therapy. J Clin Endocrinol Metabol 89:3306–3312CrossRef
12.
go back to reference Nilsson B, Gustavsson-Kadaka E, Bengtsson B-A, Jonsson B (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival and mortality. J Clin Endocrinol Metabol 85:1420–1425CrossRef Nilsson B, Gustavsson-Kadaka E, Bengtsson B-A, Jonsson B (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival and mortality. J Clin Endocrinol Metabol 85:1420–1425CrossRef
13.
go back to reference Lindholm J, Nielsen EH, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P, Stochholm K (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol 65:51–59CrossRef Lindholm J, Nielsen EH, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P, Stochholm K (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol 65:51–59CrossRef
14.
go back to reference Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P (2006) Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin Endocrinol 64:319–322CrossRef Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P (2006) Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin Endocrinol 64:319–322CrossRef
15.
go back to reference Bjørner JB, Damsgaard MT, Watt T, Bech P, Rasmussen NK, Kristensen TS, Modvig J, Thunedborg K (1997) Danish SF-36 Manual Copenhagen, LIF Bjørner JB, Damsgaard MT, Watt T, Bech P, Rasmussen NK, Kristensen TS, Modvig J, Thunedborg K (1997) Danish SF-36 Manual Copenhagen, LIF
16.
go back to reference Bech P, Rasmussen NA, Olsen LR, Nørholm V, Abildgaard W (2001) The sensitivity and specificity of the major depression inventory, using the present state examination as the index of diagnostic validity. J Affect Disord 66:159–164PubMedCrossRef Bech P, Rasmussen NA, Olsen LR, Nørholm V, Abildgaard W (2001) The sensitivity and specificity of the major depression inventory, using the present state examination as the index of diagnostic validity. J Affect Disord 66:159–164PubMedCrossRef
17.
go back to reference Statistical Yearbooks. Danmarks Statistik, Copenhagen Statistical Yearbooks. Danmarks Statistik, Copenhagen
18.
go back to reference Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef
19.
go back to reference Barahona MJ, Sojo L, Wagner AM, Bartumeus F, Oliver B, Cano P, Webb SM (2005) Determinants of neurosurgical outcome in pituitary adenomas. J Endocrinol Invest 28:787–794PubMed Barahona MJ, Sojo L, Wagner AM, Bartumeus F, Oliver B, Cano P, Webb SM (2005) Determinants of neurosurgical outcome in pituitary adenomas. J Endocrinol Invest 28:787–794PubMed
20.
go back to reference Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 57:713–717CrossRef Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 57:713–717CrossRef
21.
go back to reference Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML for The Endocrine Society’s Clinical Guidelines Subcommittee. (2006) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 91:1621–1634 Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML for The Endocrine Society’s Clinical Guidelines Subcommittee. (2006) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 91:1621–1634
22.
go back to reference Oliveira JLM, Marques-Santos C, Barreto-Filho JA, Filho RX, de Oliveira Britto AV, Souza AHO, Prado CM, Oliveira CRP, Pereira RMC, de Almeida Ribeiro Vicente T, Farias CT, Aguiar-Oliveira MH, Salvatori R (2006) Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metabol 91:2093–2099CrossRef Oliveira JLM, Marques-Santos C, Barreto-Filho JA, Filho RX, de Oliveira Britto AV, Souza AHO, Prado CM, Oliveira CRP, Pereira RMC, de Almeida Ribeiro Vicente T, Farias CT, Aguiar-Oliveira MH, Salvatori R (2006) Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metabol 91:2093–2099CrossRef
23.
go back to reference Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (QoL) in patients with acromegaly is severely impaired: use of a novel measure of QoL: acromegaly quality of life questionnaire. J Clin Endocrinol Metabol 90:3337–3341CrossRef Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (QoL) in patients with acromegaly is severely impaired: use of a novel measure of QoL: acromegaly quality of life questionnaire. J Clin Endocrinol Metabol 90:3337–3341CrossRef
24.
go back to reference Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER (2005) Assessment of quality of life in patients with uncontrolled versus controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol 63:103–110CrossRef Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER (2005) Assessment of quality of life in patients with uncontrolled versus controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol 63:103–110CrossRef
25.
go back to reference Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen LØ, Laurberg P, Feldt-Rasmussen U, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome, a population based study. J Clin Endocrinol Metabol 86:117–123CrossRef Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen LØ, Laurberg P, Feldt-Rasmussen U, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome, a population based study. J Clin Endocrinol Metabol 86:117–123CrossRef
26.
go back to reference van Aken MO, Pereira AM, Biermasz NR, van Thiel SW., Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metabol 90:3279–3286CrossRef van Aken MO, Pereira AM, Biermasz NR, van Thiel SW., Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metabol 90:3279–3286CrossRef
Metadata
Title
Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function
Authors
Eigil Husted Nielsen
Jörgen Lindholm
Peter Laurberg
Per Bjerre
Jens Sandahl Christiansen
Claus Hagen
Svend Juul
Jesper Jørgensen
Anders Kruse
Kirstine Stochholm
Publication date
01-03-2007
Published in
Pituitary / Issue 1/2007
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-007-0018-x

Other articles of this Issue 1/2007

Pituitary 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.